Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

ODYSSEY Trial Team

Producción científica › revisión exhaustiva

19 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology